Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Aleglitazar (R1439) 是一种高效的 PPARα/γ 双重激动剂,对人 PPARα 和 PPARγ 作用的 IC50 分别为 38 nM 和 19 nM。Aleglitazar 可用于 II 型糖尿病的研究。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 2,890 | 现货 | ||
5 mg | ¥ 6,590 | 现货 | ||
10 mg | ¥ 8,890 | 现货 | ||
25 mg | ¥ 13,200 | 现货 | ||
50 mg | ¥ 17,800 | 现货 | ||
100 mg | ¥ 23,800 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 6,950 | 现货 |
产品描述 | Aleglitazar (R1439) (R1439) is a potent dual PPARα/γ agonist, with IC50s of 38 nM and 19 nM for human PPARa and PPARγ, respectively. Aleglitazar can be used for the research of type II diabetes. |
靶点活性 | PPARγ:19 nM, PPARα:38 nM |
体外活性 | Aleglitazar exhibits species selectivity with respect to PPARα, with an EC50s of 50 nM, 2.26 µM and 2.34 µM for human PPARα, rat PPARα and mouse PPARα, respectively[1]. Aleglitazar (0.01-40 µM; 12-48 hours) does not significantly increase lactate dehydrogenase (LDH) release at concentrations of 0.1 µM to 20 µM, but significant increases LDH release at concentrations of 30 µM and 40 µM[2]. Aleglitazar (0.01-20 µM; 48 hours) decreases hyperglycaemic conditions (HG, glucose 25 mM)-induced apoptosis, caspase-3 activity and cytochrome-C release[2]. Aleglitazar improves cell viability in cells exposed to hyperglycaemia[2]. |
体内活性 | Aleglitazar (0.3-3.0 mg/kg; i.p.; daily; for 7 days) exerts beneficial effects on structural and functional outcomes of mild brain ischemia[3]. Aleglitazar reduces key aspects of microglia activation including NO production, release of proinflammatory cytokines, migration, and phagocytosis[3]. Aleglitazar attenuates inflammatory responses in post-ischemic brain[3]. |
别名 | RO0728804, R1439 |
分子量 | 437.51 |
分子式 | C24H23NO5S |
CAS No. | 475479-34-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 45mg/mL (102.9mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.2857 mL | 11.4283 mL | 22.8566 mL | 57.1416 mL |
5 mM | 0.4571 mL | 2.2857 mL | 4.5713 mL | 11.4283 mL | |
10 mM | 0.2286 mL | 1.1428 mL | 2.2857 mL | 5.7142 mL | |
20 mM | 0.1143 mL | 0.5714 mL | 1.1428 mL | 2.8571 mL | |
50 mM | 0.0457 mL | 0.2286 mL | 0.4571 mL | 1.1428 mL | |
100 mM | 0.0229 mL | 0.1143 mL | 0.2286 mL | 0.5714 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Aleglitazar 475479-34-6 DNA Damage/DNA Repair Metabolism PPAR RO0728804 R1439 RO-0728804 RO 0728804 R-1439 R 1439 Inhibitor inhibitor inhibit